The Anaplastic Astrocytoma drugs in development market research report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anaplastic Astrocytoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued products.

GlobalData tracks 46 drugs in development for Anaplastic Astrocytoma by 42 companies/universities/institutes. The top development phase for Anaplastic Astrocytoma is phase i with 26 drugs in that stage. The Anaplastic Astrocytoma pipeline has 39 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Anaplastic Astrocytoma pipeline products market are: Bayer, Novartis and Mustang Bio.

The key targets in the Anaplastic Astrocytoma pipeline products market include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1), Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1), and Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1).

The key mechanisms of action in the Anaplastic Astrocytoma pipeline product include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) Inhibitor with four drugs in Phase II. The Anaplastic Astrocytoma pipeline products include 12 routes of administration with the top ROA being Oral and nine key molecule types in the Anaplastic Astrocytoma pipeline products market including Small Molecule, and Oncolytic Virus.

Anaplastic Astrocytoma overview

Anaplastic astrocytoma is a grade III tumor that accounts for 2% of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking, and seizures. Anaplastic astrocytoma is most common in men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed, and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

For a complete picture of Anaplastic Astrocytoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.